mTOR信号通路的生物学功能

哺乳动物的雷帕霉素靶(mammalian target of rapamycin,mTOR)是一种非典型丝氨酸/苏氨酸蛋白激酶,可整合细胞外信号,磷酸化下游靶蛋白核糖体p70S6激酶,如S6K1及4E-BP1,影响基因转录与蛋白质翻译,从而参与调控细胞生长、增殖等过程。mTOR的生物学功能的多样性,使其成为当今生物学研究的焦点之一。mTOR与蛋白质合成、免疫、细胞运动及代谢、细胞凋亡及自噬等均有联系。     

mTOR信号通路及其与阿尔茨海默病的关系

哺乳动物雷帕霉素靶蛋白mTOR是一个进化上十分保守的蛋白激酶,属于PIKK超家族。在细胞内mTOR存在两种功能不同的复合体mTORC1和mTORC2。mTOR主要通过接受上游信号分子Rheb、TSC1/TSC2的调控来整合细胞内外信号,其下游效应器是4E-BP和p70S6K,通过影响特定mRNA的翻译调节细胞的生长和增殖。在神经系统方面,神经元的发育、突触可塑性的调节、学习和记忆的形成都依赖于适当的mTOR通路的活化。新近的研究显示,神经退行性疾病阿尔茨海默病患者表现mTOR通路的异常,在双转基因鼠中,APP和PS1表达与mTOR/P70S6K下调关联,并影响精神状态评分。mTOR信号通路生理功能和调节机制的研究对了解AD的发病机理和寻找药物靶点具有重要意义。     

慢病毒介导的mTOR敲低肝癌细胞株HepG2的构建及初步功能检测

目的:建立高效稳定的哺乳动物雷帕霉素靶蛋白(mTOR)小干扰RNA(siRNA)细胞导入方法,并对mTOR敲低的HepG2肝癌细胞株的功能进行初步检测。方法:构建了2条不同的人mTOR慢病毒siRNA载体pLenti-H1/mTOR siRNA,与3个包装质粒共转染293T细胞,包装成慢病毒后感染HepG2细胞;经嘌呤霉素筛选2周后,收集细胞进行Western印迹,检测mTOR敲减效果及其下游基因c-myc、周期蛋白D1(cyclinD1)表达水平及4E-BP1、S6K1磷酸化水平的变化。结果:RT-PCR和Western印迹结果显示,构建的pLenti-H1/mTOR siRNA能有效抑制mTOR基因的表达,敲低了mTOR蛋白水平,且沉默mTOR后其下游基因c-myc、CyclinD1的表达水平及4E-BP1、S6K1磷酸化水平降低。结论:构建了慢病毒介导RNA干扰mTOR表达载体,为进一步研究mTOR通路奠定了实验基础。     

环境变化和时序衰老过程中酵母蛋白激酶Sch9磷酸化的调控

出芽酵母(Saccharomyces cerevisiae)蛋白激酶Sch9与哺乳动物蛋白激酶S6K1同源.S6K1是哺乳动物雷帕霉素靶蛋白(mTOR)和磷脂酰肌醇3激酶(PI3K)的底物,且与很多人类疾病相关,包括肥胖症、糖尿病和癌症.Sch9和S6K1都对不同营养条件和环境胁迫条件下的细胞生长调控很重要.Sch9激活环内的磷酸化位点570位苏氨酸残基也被称为PDK1位点,而737位苏氨酸位点也被称为PDK2位点,这两个位点的磷酸化对Sch9的活性非常重要.蛋白激酶Pkh1/2磷酸化Sch9的PDK1位点,而雷帕霉素靶蛋白复合体1(TORC1)磷酸化PDK2位点.为了深入了解Sch9在细胞中的功能,阐明不同环境条件下及时序衰老过程中Sch9的PDK1和PDK2位点磷酸化的调控就显得尤为重要.利用特异性识别570位苏氨酸残基磷酸化的Sch9蛋白和特异性识别737位苏氨酸残基磷酸化的Sch9蛋白的两种抗体,对不同环境条件下和时序衰老过程中Sch9的两个位点的磷酸化调控进行了研究.研究结果揭示了Sch9的两个磷酸化位点在营养感受、胁迫应答、热量限制和时序衰老过程中的调控方式.揭示Sch9的PDK1位点磷酸化的调控与热量限制延长出芽酵母时序寿命密切相关.     

哺乳动物雷帕霉素靶蛋白通路与细胞自噬

细胞自噬作为真核生物中最基本的生命现象,广泛参与机体的多种生理和病理过程,其发生的分子机制复杂且高度保守。哺乳动物雷帕霉素靶蛋白（mammalian target of rapamycin,mTOR）通路和Beclin1及相关因子发挥了最直接的调控作用。mTOR可通过上游各信号因子的调节引起自身活性的变化,并通过调节下游复合物Atg1/ULK的生成诱导细胞自噬。弄清mTOR通路及其对自噬复合物的作用机制将有助于从分子水平上对各种肿瘤疾病进行分析和治疗。     

mTOR与S6K在衰老进程中的作用

衰老进程受到多个基因以及信号通路的调节.哺乳动物雷帕霉素靶蛋白mTOR与核糖体S6K蛋白激酶不仅调节细胞的多种生理功能,在衰老进程中也发挥着重要作用.最近的实验表明,抑制mTORC1或S6K的活性可以延长小鼠的寿限.mTOR通路通过多种方式在衰老进程中发挥作用,包括细胞自噬、代谢副产物的积累以及影响组织干细胞的数量等等.而S6K在衰老进程中的作用并不十分清晰.目前mTOR和S6K已成为研究热点,通过对这两个分子在衰老进程中作用的研究,有望找到延长寿限的方法并揭示其中的机理,本文对此作一综述.     

Sestrins在AMPK/mTOR调控细胞能量代谢中的作用研究进展

一磷酸腺苷活化蛋白激酶(AMP-activated protein kinase,AMPK)和哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)是细胞内两个重要的能量感受分子。AMPK主要调控分解代谢,而mTOR主要影响合成代谢,两者在调控细胞代谢平衡过程中发挥重要作用。Sestrins是新近发现的一类进化高度保守的应激诱导蛋白,可保护细胞免受氧化应激的损伤。此外,Sestrins还能调控AMPK/mTOR信号通路活性,从而影响组织细胞的能量代谢稳态,但其机制尚不明确。本文将主要针对Sestrins与AMPK/mTOR信号通路之间的调控关系以及对细胞能量代谢影响的最新研究进展加以综述。     

mTOR信号转导通路抑制剂及其与肿瘤耐药的研究进展

哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin, mTOR)是一种特异性的蛋白激酶,在调控细胞生长、增殖、代谢等多项生命活动中都具有重要意义。mTOR调控功能的失活与异常激活,会导致相关肿瘤和疾病的发生。近年来已有多种mTOR抑制剂用于治疗该信号转导通路异常引起的肿瘤。该文探究多种调控mTOR的信号通路和mTOR抑制剂用于肿瘤治疗的最新进展,还探讨肿瘤细胞对mTOR抑制剂产生耐药性的潜在机制和应对策略。因此,对mTOR信号通路及其调控机制的探索有助于研发全新的肿瘤治疗技术。     

mTOR信号通路与衰老及衰老相关重大疾病

衰老引起多器官功能衰减,导致各种衰老相关代谢、心血管重大疾病发生和发展.哺乳动物雷帕霉素靶蛋白/雷帕霉素机能靶蛋白(mammalian/mechanistic target of rapamycin,mTOR)信号通路作为生长、发育、代谢、免疫、癌症等生理活动的主要调控者,通过影响细胞自噬、内质网应激、线粒体等形成复杂调控网络,在衰老与长寿中发挥关键作用.mTOR信号通路与许多衰老相关重大疾病(如代谢综合征、心血管疾病、神经退行性病变、肿瘤等)的发生发展密切相关,故以mTOR为靶点的药物开发与应用是未来延缓衰老及治疗衰老相关疾病的热点之一.     

综述: mTOR信号通路与衰老及衰老相关重大疾病

衰老引起多器官功能衰减,导致各种衰老相关代谢、心血管重大疾病发生和发展.哺乳动物雷帕霉素靶蛋白/雷帕霉素机能靶蛋白(mammalian/mechanistic target of rapamycin,mTOR)信号通路作为生长、发育、代谢、免疫、癌症等生理活动的主要调控者,通过影响细胞自噬、内质网应激、线粒体等形成复杂调控网络,在衰老与长寿中发挥关键作用.mTOR信号通路与许多衰老相关重大疾病(如代谢综合征、心血管疾病、神经退行性病变、肿瘤等)的发生发展密切相关,故以mTOR为靶点的药物开发与应用是未来延缓衰老及治疗衰老相关疾病的热点之一.     

Zinc stimulates glucose consumption by modulating the insulin signaling pathway in L6 myotubes: essential roles of Akt–GLUT4, GSK3β and mTOR–S6K1

The present study was performed to evaluate the insulin-like effects of zinc in normal L6 myotubes as well as its ability to alleviate insulin resistance. Glucose consumption was measured in both normal and insulin-resistant L6 myotubes. Western blotting and immunofluorescence revealed that zinc exhibited insulin-like glucose transporting effects by activating key markers that are involved in the insulin signaling cascade (including Akt, GLUT4 and GSK3β), and downregulating members of the insulin signaling feedback cascade such as mammalian target of rapamycin (mTOR) and ribosomal protein S6 kinase (S6K1). In normal L6 myotubes, zinc enhanced glucose consumption via a mechanism that might involve the activation of Akt phosphorylation, glucose transporter 4 (GLUT4) translocation and GSK3β phosphorylation. In contrast, zinc exerted insulin-mimetic effects in insulin-resistant L6 myotubes by upregulating Akt phosphorylation, GLUT4 translocation and GSK3β phosphorylation, and downregulating the expression of mTOR and S6K1. In conclusion, zinc might enhance glucose consumption by modulating insulin signaling pathways including Akt–GLUT4, GSK3β, mTOR and S6K1.     

Clofibrate treatment promotes branched-chain amino acid catabolism and decreases the phosphorylation state of mTOR, eIF4E-BP1, and S6K1 in rat liver

Leucine stimulates protein synthesis by modulating the mammalian target of rapamycin (mTOR) signaling pathway. We hypothesized that promotion of the branched-chain amino acid (BCAA) catabolism might influence the leucine-induced protein synthesis. Clofibric acid (an active metabolite of clofibrate) is known to promote the BCAA catabolism by activation of branched-chain alpha-keto acid dehydrogenase complex (BCKDC), the rate-limiting enzyme of the BCAA catabolism. In the present study, we examined the phosphorylation state of mTOR, eukaryotic initiation factor 4E-binding protein-1 (4E-BP1), and ribosomal protein S6 kinase 1 (S6K1) in liver of rats with or without activation of the BCKDC by clofibrate treatment. Clofibrate-treated rats were prepared by oral administration of clofibrate 5 h before sacrifice. In order to stimulate phosphorylation of components in the mTOR signaling pathway, rats were orally administered with leucine 1 h before sacrifice. Clofibrate treatment almost fully activated hepatic BCKDC and significantly decreased the plasma leucine concentration in rats without leucine administration, resulting in decreased mTOR and 4E-BP1 phosphorylation. Similarly, in rats administered with leucine, clofibrate treatment attenuated the predicted increase in plasma leucine concentration as well as the phosphorylation of mTOR, 4E-BP1, and S6K1. These results suggest that BCAA catabolism enhanced by clofibrate treatment has significant influences on the leucine-induced activation of translation initiation processes.     

Leucine-stimulated mTOR signaling is partly attenuated in skeletal muscle of chronically uremic rats

The branched-chain amino acid leucine stimulates muscle protein synthesis in part by directly activating the mTOR signaling pathway. Furthermore, leucine, if given in conjunction with resistance exercise, enhances the exercise-induced mTOR signaling and protein synthesis. Here we tested whether leucine can activate the mTOR anabolic signaling pathway in uremia and whether it can enhance work overload (WO)-induced signaling through this pathway. Chronic kidney disease (CKD) and control rats were studied after 7 days of surgically induced unilateral plantaris muscle WO and a single leucine or saline load. In the basal state, 4E-BP1 phosphorylation was modestly depressed in non-WO muscle of CKD rats, whereas rpS6 phosphorylation was nearly completely suppressed. After oral leucine mTOR, S6K1 and rpS6 phosphorylation increased similarly in both groups, whereas the phospho-4E-BP1 response was modestly attenuated in CKD. WO alone activated the mTOR signaling pathway in control and CKD rats. In WO CKD, muscle leucine augmented mTOR and 4E-BP1 phosphorylation, but its effect on S6K1 phosphorylation was attenuated. Taken together, this study has established that the chronic uremic state impairs basal signaling through the mTOR anabolic pathway, an abnormality that may contribute to muscle wasting. However, despite this abnormality, leucine can stimulate this signaling pathway in CKD, although its effectiveness is partially attenuated, including in skeletal muscle undergoing sustained WO. Thus, although there is some resistance to leucine in CKD, the data suggest a potential role for leucine-rich supplements in the management of uremic muscle wasting.     

Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins

Signaling through the mammalian target of rapamycin (mTOR) controls cell size and growth as well as other functions, and it is a potential therapeutic target for graft rejection, certain cancers, and disorders characterized by inappropriate cell or tissue growth. mTOR signaling is positively regulated by hormones or growth factors and amino acids. mTOR signaling regulates the phosphorylation of several proteins, the best characterized being ones that control mRNA translation. Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) undergoes phosphorylation at multiple sites. Here we show that amino acids regulate the N-terminal phosphorylation sites in 4E-BP1 through the RAIP motif in a rapamycin-insensitive manner. Several criteria indicate this reflects a rapamycin-insensitive output from mTOR. In contrast, the insulin-stimulated phosphorylation of the C-terminal site Ser64/65 is generally sensitive to rapamycin, as is phosphorylation of another well-characterized target for mTOR signaling, S6K1. Our data imply that it is unlikely that mTOR directly phosphorylates Thr69/70 in 4E-BP1. Although 4E-BP1 and S6K1 bind the mTOR partner, raptor, our data indicate that the outputs from mTOR to 4E-BP1 and S6K1 are distinct. In cells, efficient phosphorylation of 4E-BP1 requires it to be able to bind to eIF4E, whereas phosphorylation of 4E-BP1 by mTOR in vitro shows no such preference. These data have important implications for understanding signaling downstream of mTOR and the development of new strategies to impair mTOR signaling.     

Hepatitis C virus activates the mTOR/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance

Hepatitis C virus (HCV) infection significantly increases the prevalence of type 2 diabetes mellitus (T2DM). Insulin receptor substrate 1 (IRS-1) plays a key role in insulin signaling, thus enabling metabolic regulation in mammalian cells. We have previously shown that HCV infection modulates phosphorylation of Akt, a downstream target of IRS-1. In this study, we further examined the status of total IRS-1 and the downstream regulation of the Akt pathway in understanding mTOR/S6K1 signaling using HCV genotype 2a (clone JFH1)-infected hepatocytes. Inhibition of IRS-1 expression was observed in HCV-infected hepatocytes compared to that in a mock-infected control. The status of the tuberous sclerosis complex (TSC-1/TSC-2) was significantly decreased after HCV infection of human hepatocytes, showing a modulation of the downstream Akt pathway. Subsequent study indicated an increased level of Rheb and mTOR expression in HCV-infected hepatocytes. Interestingly, the phosphoS6K1 level was higher in HCV-infected hepatocytes, suggesting a novel mechanism for IRS-1 inhibition. Ectopic expression of TSC-1/TSC-2 significantly recovered the IRS-1 protein expression level in HCV-infected hepatocytes. Further analyses indicated that HCV core protein plays a significant role in modulating the mTOR/S6K1 signaling pathway. Proteasome inhibitor MG 132 recovered IRS-1 and TSC1/2 expression, suggesting that degradation occurred via the ubiquitin proteasome pathway. A functional consequence of IRS-1 inhibition was reflected in a decrease in GLUT4 protein expression and upregulation of the gluconeogenic enzyme PCK2 in HCV-infected hepatocytes. Together, these observations suggested that HCV infection activates the mTOR/S6K1 pathway in inhibiting IRS-1 function and perturbs glucose metabolism via downregulation of GLUT4 and upregulation of PCK2 for insulin resistance.     

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

The mammalian target of rapamycin (mTOR) integrates nutrient and mitogen signals to regulate cell growth (increased cell mass and cell size) and cell division. The immunosuppressive drug rapamycin inhibits cell cycle progression via inhibition of mTOR; however, the signaling pathways by which mTOR regulates cell cycle progression have remained poorly defined. Here we demonstrate that restoration of mTOR signaling (by using a rapamycin-resistant mutant of mTOR) rescues rapamycin-inhibited G(1)-phase progression, and restoration of signaling along the mTOR-dependent S6K1 or 4E-BP1/eukaryotic translation initiation factor 4E (eIF4E) pathways provides partial rescue. Furthermore, interfering RNA-mediated reduction of S6K1 expression or overexpression of mTOR-insensitive 4E-BP1 isoforms that block eIF4E activity inhibit G(1)-phase progression individually and additively. Thus, the activities of both the S6K1 and 4E-BP1/eIF4E pathways are required for and independently mediate mTOR-dependent G(1)-phase progression. In addition, overexpression of constitutively active mutants of S6K1 or wild-type eIF4E accelerates serum-stimulated G(1)-phase progression, and stable expression of wild-type S6K1 confers a proliferative advantage in low-serum-containing media, suggesting that the activity of each of these pathways is limiting for cell proliferation. These data demonstrate that, as for the regulation of cell growth and cell size, the S6K1 and 4E-BP1/eIF4E pathways each represent critical mediators of mTOR-dependent cell cycle control.     

TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function

BACKGROUND: The mammalian target of rapamycin, mTOR, is a serine/threonine kinase that controls cell growth and proliferation via the translation regulators eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1) and ribosomal protein S6 kinase 1 (S6K1). We recently identified a TOR signaling (TOS) motif in the N terminus of S6K1 and the C terminus of 4E-BP1 and demonstrated that in S6K1, the TOS motif is necessary to facilitate mTOR signaling to phosphorylate and activate S6K1. However, it is unclear how the TOS motif in S6K1 and 4E-BP1 mediates mTOR signaling. RESULTS: Here, we show that a functional TOS motif is required for 4E-BP1 to bind to raptor (a recently identified mTOR-interacting protein), for 4E-BP1 to be efficiently phosphorylated in vitro by the mTOR/raptor complex, and for 4E-BP1 to be phosphorylated in vivo at all identified mTOR-regulated sites. mTOR/raptor-regulated phosphorylation is necessary for 4E-BP's efficient release from the translational initiation factor eIF4E. Consistently, overexpression of a mutant of 4E-BP1 containing a single amino acid change in the TOS motif (F114A) reduces cell size, demonstrating that mTOR-dependent regulation of cell growth by 4E-BP1 is dependent on a functional TOS motif. CONCLUSIONS: Our data demonstrate that the TOS motif functions as a docking site for the mTOR/raptor complex, which is required for multisite phosphorylation of 4E-BP1, eIF4E release from 4E-BP1, and cell growth.     

Role of adenosine 5'-monophosphate-activated protein kinase subunits in skeletal muscle mammalian target of rapamycin signaling

AMP-activated protein kinase (AMPK) is an important energy-sensing protein in skeletal muscle. Mammalian target of rapamycin (mTOR) mediates translation initiation and protein synthesis through ribosomal S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1). AMPK activation reduces muscle protein synthesis by down-regulating mTOR signaling, whereas insulin mediates mTOR signaling via Akt activation. We hypothesized that AMPK-mediated inhibitory effects on mTOR signaling depend on catalytic alpha2 and regulatory gamma3 subunits. Extensor digitorum longus muscle from AMPK alpha2 knockout (KO), AMPK gamma3 KO, and respective wild-type (WT) littermates (C57BL/6) were incubated in the presence of 5-aminoimidazole-4-carboxamide-1-beta-d-ribonucleoside (AICAR), insulin, or AICAR plus insulin. Phosphorylation of AMPK, Akt, and mTOR-associated signaling proteins were assessed. Insulin increased Akt Ser473 phosphorylation (P < 0.01), irrespective of genotype or presence of AICAR. AICAR increased phosphorylation of AMPK Thr172 (P < 0.01) in WT but not KO mice. Insulin stimulation increased phosphorylation of S6K1 (Thr389), ribosomal protein S6 (Ser235/236), and 4E-BP1 (Thr37/46) (P < 0.01) in WT, AMPK alpha2 KO, and AMPK gamma3 KO mice. However, in WT mice, preincubation with AICAR completely inhibited insulin-induced phosphorylation of mTOR targets, suggesting mTOR signaling is blocked by prior AMPK activation. The AICAR-induced inhibition was partly rescued in extensor digitorum longus muscle from either alpha2 or gamma3 AMPK KO mice, indicating functional alpha2 and gamma3 subunits of AMPK are required for the reduction in mTOR signaling. AICAR alone was without effect on basal phosphorylation of S6K1 (Thr389), ribosomal protein S6 (Ser235/236), and 4E-BP1 (Thr37/46). In conclusion, functional alpha2 and gamma3 AMPK subunits are required for AICAR-induced inhibitory effects on mTOR signaling.     

The mammalian target of rapamycin (mTOR) partner,raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif

The mammalian target of rapamycin (mTOR) controls multiple cellular functions in response to amino acids and growth factors, in part by regulating the phosphorylation of p70 S6 kinase (p70S6k) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1). Raptor (regulatory associated protein of mTOR) is a recently identified mTOR binding partner that also binds p70S6k and 4E-BP1 and is essential for TOR signaling in vivo. Herein we demonstrate that raptor binds to p70S6k and 4E-BP1 through their respective TOS (conserved TOR signaling) motifs to be required for amino acid- and mTOR-dependent regulation of these mTOR substrates in vivo. A point mutation of the TOS motif also eliminates all in vitro mTOR-catalyzed 4E-BP1 phosphorylation and abolishes the raptor-dependent component of mTOR-catalyzed p70S6k phosphorylation in vitro. Raptor appears to serve as an mTOR scaffold protein, the binding of which to the TOS motif of mTOR substrates is necessary for effective mTOR-catalyzed phosphorylation in vivo and perhaps for conferring their sensitivity to rapamycin and amino acid sufficiency.     

Hypercholesterolemia is associated with hyperactive cardiac mTORC1 and mTORC2 signaling

Nutritional excess and hyperlipidemia increase the heart’s susceptibility to ischemic injury. Mammalian target of rapamycin (mTOR) controls the cellular response to nutritional status and may play a role in ischemic injury. To explore the effect of hypercholesterolemia on cardiac mTOR signaling, we assessed mTOR signaling in hypercholesterolemic swine (HC) that are also susceptible to increased cardiac ischemia-reperfusion injury. Yucatan pigs were fed a high-fat/high-cholesterol diet for 4 weeks to induce hypercholesterolemia, and mTOR signaling was measured by immunoblotting and immunofluorescence in the non-ischemic left ventricular area. Total myocardial mTOR and raptor levels were markedly increased in the HC group compared to the normocholesterolemic group, and directly correlated with serum cholesterol levels. mTOR exhibited intense perinuclear staining in myocytes only in the HC group. Hypercholesterolemia was associated with hyperactive signaling upstream and downstream of both mTOR complexes, including myocardial Akt, S6K1, 4EBP1, S6, and PKC-alpha, increased levels of cardiac hypertrophy markers, and a trend toward lower levels of myocardial autophagy. Hypercholesterolemia can now be added to the growing list of conditions associated with aberrant mTOR signaling. Hypercholesterolemia produces a unique profile of alterations in cardiac mTOR signaling, which is a potential target in cardiac diseases associated with hypercholesterolemia and nutritional excess.